The acquired company, CymaBay Therapeutics, is a Newark, Calif.-based drug manufacturer focused on primary biliary cholangitis. PBC is a rare chronic liver disease that mainly affects women, with a prevalence of 130,000 people in the U.S.
Gilead’s purchase adds CymaBay’s lead drug candidate, seladelpar, to its portfolio, according to a Gilead news release. The FDA is reviewing seladelpar’s tentative approval, and its decision is expected by Aug. 14.
